ShareVault Web Panel: Adoptive Cell Therapy vs. Solid Tumors

Date and Time

Thursday Nov 21, 2019
2:00 PM - 3:30 PM EST

November 21
2:00 - 3:30 p.m. EST

Location

Web Panel

Fees/Admission

Sign up ! If you can't attend the live session, register anyway, and ShareVault will send you the recording when it becomes available.

Website

Learn more!

ShareVault Web Panel: Adoptive Cell T...

Description

ShareVault Announces Web Panel on Adoptive Cell Therapy vs. Solid Tumors: Who, How, and When?

Just 7 years since Novartis paid UPenn $20M to access Carl June’s anti-CD19 CAR-T technology, the field of adoptive cell therapy (ACT) in cancer has expanded dramatically, both in investment activity and technology proliferation. At present, it is estimated that there are at least 150 pre-commercial ACT-focused companies in the US and EU alone, many of which are less than 5 years old. While some of these newcos are pursuing fast-follower strategies, many are developing novel technology platforms, each with a unique value proposition that has proven sufficient to incentivize investors.

While ACTs have yet to score any major wins in solid tumors beyond the early success of TILs, many early-stage clinical programs are slated to readout within the next few years. Join ShareVault on Thursday, November 21 as they ask a panel of experts their views on the most exciting new developments, what they seek to license, what data they must see to do deals, and more.

ShareVault Web Panel: Adoptive Cell Therapy vs. Solid Tumors

Date and Time

Location

Fees/Admission

Website

Description

Quicklinks

Get In Touch!

ShareVault Web Panel: Adoptive Cell Therapy vs. Solid Tumors

Date and Time

Location

Fees/Admission

Website

Set a Reminder

Description

Set a Reminder

Quicklinks

Get In Touch!